Cargando…
Potential sources of interference on Abeta immunoassays in biological samples
Therapeutic products that depend on the use of an in vitro diagnostic biomarker test to confirm their effectiveness are increasingly being developed. Use of biomarkers is particularly meaningful in the context of selecting the patient population where the therapeutic treatment is believed to be effi...
Autores principales: | Vanderstichele, Hugo, Stoops, Erik, Vanmechelen, Eugeen, Jeromin, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580396/ https://www.ncbi.nlm.nih.gov/pubmed/23082750 http://dx.doi.org/10.1186/alzrt142 |
Ejemplares similares
-
Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease
por: Thijssen, Elisabeth H., et al.
Publicado: (2021) -
Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment
por: Vanderstichele, Hugo Marcel, et al.
Publicado: (2019) -
Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X
por: Antonios, Gregory, et al.
Publicado: (2015) -
Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review
por: Moreth, Jens, et al.
Publicado: (2013) -
Site specific NMR characterization of abeta-40 oligomers cross seeded by abeta-42 oligomers
por: Chang, Han-Wen, et al.
Publicado: (2022)